A VSV-based assay quantifies coronavirus Mpro/3CLpro/Nsp5 main protease activity and chemical inhibition

作者：Emmanuel Heilmann, Francesco Costacurta, Stephan Geley, Seyad Arad Mogadashi, André Volland, Bernhard Rupp, Reuben S. Harris, Dorotheé von Laer · 发表于：Communications Biology · 年份：2022 · DOI：10.1038/s42003-022-03277-0 · 被引用次数：31 · 研究领域：Computational Drug Discovery Methods、SARS-CoV-2 and COVID-19 Research、thermodynamics and calorimetric analyses

Abstract Protease inhibitors are among the most powerful antiviral drugs. However, for SARS-CoV-2 only a small number of protease inhibitors have been identified thus far and there is still a great need for assays that efficiently report protease activity and inhibition in living cells. Here, we engineer a safe VSV-based system to report both gain- and loss-of-function of coronavirus main protease (M pro /3CLpro/Nsp5) activity in living cells. We use SARS-CoV-2 3CLpro in this system to confirm susceptibility to known inhibitors (boceprevir, GC376, PF-00835231, and PF-07321332/nirmatrelvir) and reevaluate other reported inhibitors (baicalein, ebselen, carmofur, ethacridine, ivermectin, masitinib, darunavir, and atazanavir). Moreover, we show that the system can be adapted to report both the function and the chemical inhibition of proteases from different coronavirus species as well as from distantly related viruses. Together with the fact that live cell assays also reflect compound permeability and toxicity, we anticipate that this system will be useful for both identification and optimization of additional coronavirus protease inhibitors.